The clinical efficacy of venlafaxine extended release formulations and paroxetine in treatment of depression

Objective To investigate efficacy and safety of venlafaxine extended release formulations and paroxetine in treatment of depression. Methods 60 patients with depression from June 2012 to March 2013 in our hospital were randomly divided into two groups, patients in group A were given venlafaxine extended release formulations treatment,patients in group B were given paroxetine treatment, they were all treated for two months, and then the Hamilton depression rating scale(HAMD), the overall clinical rating scale(CGI) were used to evaluate the therapeutic effects,and adverse reactions were observed. Results After treatment, HAMD, CGI score were lower than that before treatment(P0.05). After 1 week treatment, HAMD scores of group A were significantly lower than group B( P0.05); 4 and 8weeks after treatment, HAMD score of two groups showed no significant difference( P 0.05); After 1,4,8 weeks treatment CGI scores between two groups were not statistically significant( P0.05); and treatment efficiency of two groups compared, the difference was not significant(P0.05). During the treatment, mouth dry, constipation, nausea,abnormal electrocardiogram and other adverse reactions were all found in two groups, but the difference was not significant, and the adverse reactions were reduced or disappeared after symptomatic treatment, and did not affect the treatment.Conclusion Venlafaxine extended release formulations and paroxetine in the treatment of depression has no significant difference in efficacy, and the safety is high, but the onset time of venlafaxine is short, so it is worthy of application.